Navigation Links
Garbage bug may help lower the cost of biofuel
Date:12/4/2012

cuts the xylan into small pieces and a protein that binds to the pieces and brings them inside the cell. Enzymes within the cell metabolize the sugar.

The reason that this microbe, unlike most others used to make biofuels, is able to degrade xylan is that it has evolved an enzyme that allows it to remove the side chains, or decorations, that are part of xylan's structure. They hinder the degradation process by preventing complete accessibility of the enzymes to the sugar chain.

Once the side chains have been removed, another enzyme in the microbe breaks the sugar chain down into single sugars, or xylose. Other enzymes within the cell then metabolize the xylose.

Having the enzymes next to each other on the genome is convenient for scientists who are working on engineering microbes that can degrade both cellulose and hemicellulose. The cluster could be designed as a cassette and put into a microbe that normally degrades only cellulose.

Moreover, being next to each other allows them to work efficiently. "You have a set of enzymes that have co-evolved," Cann explained. "If they have co-evolved over millions of years, it means they have been fine-tuned to work together."

Another advantage of Caldanaerobius polysaccharolyticus is that it is a thermophilic bacterium, and its enzymes are resistant to temperatures as high as 70 degrees Celsius. Biofuel fermentation is usually done at 37 degrees Celsius, a temperature at which most microbes can survive. This means that the material in the fermentation vats is easily contaminated.

The next step for Cann and his collaborators is to develop techniques for transferring this gene cluster, which is quite large, into microbes.


'/>"/>

Contact: Susan Jongeneel
sjongene@illinois.edu
217-333-3291
University of Illinois College of Agricultural, Consumer and Environmental Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. New research lowers past estimates of sea-level rise
2. Lower dosage CT-guided lung biopsy protocol maintains quality, minimizes exposure
3. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
4. Study finds circle hooks lower catch rate for offshore anglers
5. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
6. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
7. Scientists discover switch in plants to create flowers
8. Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar
9. Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats
10. Supercharged safflower
11. Its in the genes: Research pinpoints how plants know when to flower
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Biological and Environmental Nanotechnology (CBEN) have developed a ... human cell that is programmed to light up ... of particular proteases is a common hallmark of ... the September issue of the journal Biochemical and ...
... The most detailed analysis to date of how humans differ ... that natural selection has shaped the recent evolution of our ... Celera Diagnostics. , In a study published in the ... 11,624 genes, comparing how genes vary not only among 39 ...
... a 'living gel' that could be applied to the ... , The researchers genetically modified bacteria that are normally ... protein that stops the HIV virus from infecting cells. ... the internal body surfaces where HIV transmission can occur ...
Cached Biology News:'Smart' nanoprobes light up disease 2Cornell finds natural selection in humans 2Cornell finds natural selection in humans 3Living anti-HIV gel shows early promise 2
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... 27, 2015  Ceres, Inc. (Nasdaq: CERE ), ... patent for a genetic sequence derived from soybean, covering ... product development and plant transformation. The company believes that ... that are the target of a class of commercial ... commercial license to the innovation, including an opportunity for ...
(Date:5/27/2015)... MARLBOROUGH, Mass. , May 27, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today provided an update on the status of ... Stock. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... there were 3,085 and 21 shares of Series ...
(Date:5/27/2015)... ­ Caris Life Sciences®, a leading biotechnology ... today announced it has appointed the Levine Cancer Institute, ... site in the Caris Centers of Excellence for Precision ... is one of the largest cancer care providers throughout ... patients annually. Derek Raghavan , M.D., Ph.D., President ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... HARBIN, China , May ... ("China Sky One Medical" or "the Company") (Nasdaq: ... producing over-the-counter drugs in, the People,s Republic of ... Long,Pharmaceutical Company ("Tian Long") subsidiary successfully obtained renewal,of ...
... NEW YORK , May 27 Pfizer Inc. (NYSE: ... to the EMPHASIS-HF trial early on the recommendations of the trial,s ... analysis by the independent Data Safety Monitoring Committee (DSMC) of the ... early according to the protocol pre-defined stopping rules. , ...
... in the College of Engineering at Virginia Tech, has ... to support development of a carbon nanotube-enhanced composite for ... huge wind turbine blades. Powe awards provide seed ... member institutions. These awards are intended to enrich the ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 2Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 4Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 5Powe Award supports development of nanocomposites to monitor wind turbine blade structure 2